FightMND Grant Awards Further Work Into ALS, Other Motor Neuron Diseases

FightMND Grant Awards Further Work Into ALS, Other Motor Neuron Diseases
4.3
(8)

Three grants given researchers at two centers in Australia will advance work into ways of preserving nerve cells in people with amyotrophic lateral sclerosis (ALS), and other motor neuron diseases.

The grants, totaling AU$1.5 million (about $1.1 million), came from FightMND, an Australian nonprofit patient advocacy group.

Lezanne Ooi, PhD, an associate professor of biological sciences at the University of Wollongong and Illawarra Health and Medical Research Institute, was awarded a two-year, $250,000 Impact Grant to investigate whether electric signals from motor nerve cells might be used to protect these cells in people with motor neuron disease (MND).

MNDs are progressive neurological disorders that destroy the motor neurons controlling skeletal muscles, which are essential for walking, breathing, and swallowing. ALS is a quickly progressing form of MND; other forms include spinal muscular atrophy and primary lateral sclerosis.

Ooi’s previous work includes efforts to create nerve cells in the lab, using  induced pluripotent stem cells. Taken from skin or blood of ALS patients, these stem cells can be programmed to generate nerve cells that aid in disease understanding and possibly the discovery of treatments.

Justin Yerbury, PhD, a professor of molecular biology at both the university and the institute, received an AU$1 million Drug Development Grant to further work into a combination treatment for both familial and sporadic forms of MND.

Combination therapies contain multiple medicinal compounds that act on different facets of the same disorder.

“We believe that a three-pronged approach targeting distinct and complementary aspects of the underlying molecular causes of MND will be a more effective approach,” said Yerbury, who was diagnosed with a genetic form of this disease in 2016 and is now paralyzed. The grant will enable him to bring a post-doctoral researcher and assistant researcher into the project.

Yerbury turned from professional basketball to scientific research following the diagnosis and death of several family members from MND, a decade before his own disorder became evident.

He was awarded the Order of Australia in recognition of his scientific achievements earlier this year.

Yerbury also shared a separate $250,000 grant with his former student Luke McAlary, PhD. This grant will fund the use of a new technology to examine, at the single-protein level, the proteins that form the toxic deposits in neurons underlying MND.

“We want to define how the shape of the proteins may give rise to MND and characterize differences between patients,” Yerbury said. “By knowing the shape that these proteins take, we can identify specific parts of the proteins to target with therapies.”

“We not only want to examine the potential causes, but also the potential treatments for MND. In the next phase of the investigation, we hope to see improvements in our research output and also in our capability to examine drugs for translation into patients,” McAlary added.

FightMND has supported both past and ongoing clinical trials into potential ALS therapies.

“FightMND has done an amazing job raising awareness and funding during a period of decline in government funding,” Yerbury said. “It shows that Australians are passionate about finding a cure for this devastating disease.”

 

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Total Posts: 45
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
Latest Posts
  • SLS-005, orphan drug designation
  • Radicava study
  • AT-1501

How useful was this post?

Click on a star to rate it!

Average rating 4.3 / 5. Vote count: 8

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Pin It on Pinterest

Share This